Loading clinical trials...
Loading clinical trials...
A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Conditions
Interventions
sorafenib tosylate
cisplatin
+2 more
Locations
1
United States
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Columbus, Ohio, United States
Start Date
April 14, 2014
Primary Completion Date
April 20, 2017
Completion Date
April 20, 2017
Last Updated
May 24, 2018
NCT00939627
NCT01847326
NCT00095628
NCT00397384
NCT00114283
NCT00513435
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions